Exicure Announces Participation in 10th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Exicure, Inc. (Nasdaq: XCUR) has announced its participation in 1x1 meetings with institutional investors at the 10th Annual SV Leerink Global Healthcare Conference from February 24 to 26, 2021. The company focuses on gene regulatory and immunotherapeutic drug development using its proprietary Spherical Nucleic Acid (SNA™) technology. Exicure is currently advancing its drug candidate XCUR-FXN for Friedreich’s ataxia and conducting a Phase 1b/2 trial for AST-008 in advanced solid tumors. The company is headquartered in Chicago, IL, with an office in Cambridge, MA.

Positive

• Participation in a significant healthcare conference may enhance investor relations.
• Ongoing clinical trials for drug candidates could indicate progress in drug development.

Negative

• None.

Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced participation in a series of 1x1 meetings with institutional investors at the 10th Annual SV Leerink Global Healthcare Conference, occurring February 24 – 26, 2021.

To schedule a 1x1 meeting with Exicure, please view availability on the conference page here.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immune-oncology, inflammatory diseases and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN an SNA–based therapeutic candidate, for the treatment of Friedreich’s ataxia (FA). Exicure’s drug candidate AST-008 is currently in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is in Chicago, IL and has an office in Cambridge, MA.

For more information, visit Exicure’s website at www.exicuretx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005101/en/

FAQ

What is Exicure, Inc. (XCUR) participating in February 2021?

Exicure, Inc. is participating in 1x1 meetings with institutional investors at the 10th Annual SV Leerink Global Healthcare Conference from February 24 to 26, 2021.

What drug candidates is Exicure developing?

Exicure is developing XCUR-FXN for Friedreich’s ataxia and AST-008, which is in a Phase 1b/2 clinical trial for advanced solid tumors.

Where is Exicure, Inc. located?

Exicure, Inc. is headquartered in Chicago, IL, and has an office in Cambridge, MA.

What technology does Exicure use for its drug development?

Exicure utilizes proprietary Spherical Nucleic Acid (SNA™) technology for developing its therapeutics.